Pharmacokinetics-pharmacodynamics of tazobactam in combination with piperacillin in an in vitro infection model

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2075-2080

  Nicasio, Anthony M ^a   Van Scoy, Brian D ^b   Mendes, Rodrigo E ^c   Castanheira, Mariana ^c   Bulik, Catharine C ^b   Okusanya, Olanrewaju O ^b,f   Bhavnani, Sujata M ^b   Forrest, Alan ^b   Jones, Ronald N ^c   Friedrich, Lawrence V ^d   Steenbergen, Judith N ^d,g   Ambrose, Paul G ^b,e  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^c JMI LABORATORIES   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g Transcept Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN; TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BETA-LACTAMASE CTX-M-15; PENICILLANIC ACID;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL LOAD; CELL KILLING; COLONY FORMING UNIT; DRUG EFFICACY; ENZYME SYNTHESIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; CHEMISTRY; COMBINATION DRUG THERAPY; COMPUTER SIMULATION; DRUG EFFECTS; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; PLASMID; STATISTICAL MODEL; TRANSGENIC ORGANISM;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; COMPUTER SIMULATION; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; GENE EXPRESSION; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; ORGANISMS, GENETICALLY MODIFIED; PENICILLANIC ACID; PIPERACILLIN; PLASMIDS; TRANSCRIPTION, GENETIC;

EID: 84963736129     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02747-15     Document Type: Article

References (13)

1. Toussaint KA, Gallagher JC. 2015. β-Lactam/β-lactamase inhibitor combinations: from then to now. Ann Pharmacother 49:86-98. http://dx.doi.org/10.1177/1060028014556652.
2. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. 2007. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 5:365-383. http://dx.doi.org/10.1586/14787210.5.3.365.
3. Desai NR, Shah SM, Cohen J, McLaughlin M, Dalal HR. 2008. Zosyn (piperacillin/tazobactam) reformulation: expanded compatibility and coadministration with lactated Ringer's solutions and selected aminoglycosides. Ther Clin Risk Manag 4:303-314.
4. World Health Organization. Accessed 28 June 2015 Antimicrobial resistance: global report on surveillance. WHO, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748-eng.pdf.
5. Boucher HW, Talbot GH, Benjamin DK, Jr, Bradlet J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D, Infectious Diseases Society of America. 2013. 10 × '20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685-1694. http://dx.doi.org/10.1093/cid/cit152.
6. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86. http://dx.doi.org/10.1086/510079.
7. Lee GC, Liou H, Yee R, Quan CF, Neldner K. 2012. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients. Clin Ther 34:2297-2300. http://dx.doi.org/10.1016/j.clinthera.2012.11.005.
8. Yost RJ, Cappelletty DM, RECEIPT Study Group. 2011. The retrospective cohort of extended-infusion piperacillin-tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy 31:767-775. http://dx.doi.org/10.1592/phco.31.8.767.
9. Craig WA. 1998. Pharmacokinetic/pharmacodynamics parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12. http://dx.doi.org/10.1086/516284.
10. Van Scoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother 57:2809-2814. http://dx.doi.org/10.1128/AAC.02513-12.
11. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Van Scoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother 57:5924-5930. http://dx.doi.org/10.1128/AAC.00656-13.
13. Densen P. 2010. Complement, p 77-98. In Bennett JE, Dolin R, Blaser MJ, Mandell GL, DouglasRG (ed), Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed, vol 1. Churchill Livingstone Elsevier, Philadelphia, PA.